MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults.
Level 2 - randomized trial
Double-blind, placebo-controlled randomized trial
PubMed 35182418 · doi:10.1093/gerona/glac049
What was done
In a double-blind, placebo-controlled trial, 32 overweight or obese adults aged 55 to 80 years were block-randomized (stratified by sex) to receive oral MIB-626 (a microcrystalline β-NMN formulation) at 1,000 mg once daily, 1,000 mg twice daily, or placebo for 14 days. Blood and urine concentrations of NMN, NAD, and the NAD metabolome were measured using liquid chromatography-tandem mass spectrometry.
What was found
MIB-626 was well tolerated, with adverse event rates comparable across groups. By Day 14, blood NMN mean AUClast increased by 1.7-fold above baseline in the 1,000 mg once-daily group and 3.7-fold in the twice-daily group, significantly exceeding placebo. MIB-626 produced substantial dose-dependent increases in blood NAD and its downstream metabolites on Days 8 and 14. Changes in NMN and NAD were not associated with age, sex, or BMI. Negligible unmodified NMN was detected in urine.
Why it matters
This study provides human pharmacokinetic and pharmacodynamic evidence that a specific oral β-NMN polymorph formulation reliably elevates circulating NAD levels in a dose-dependent manner over a 14-day window.
Limits
The trial had a small sample size (n=32) and a short 14-day intervention period. The cohort was limited to overweight or obese adults aged 55–80 years. The study was designed to assess pharmacokinetics, safety, and biomarker levels rather than clinical efficacy or functional health outcomes.